Introduction {#s1}
============

Globally, remarkable progress has been made in improving access to ARVs whereby treatment coverage of 65% (9.7 million people) [@pone.0086305-WHO1] was achieved by end of 2012 compared to the 2015 target of 15 million agreed by United Nations Member States in June 2011 [@pone.0086305-United1]. Of all these HIV-infected people already on ART, 16% (1.6million people) were put on ART in 2012 alone [@pone.0086305-WHO1]. In Sub-Saharan Africa (SSA) which constitutes 69% of HIV infections globally, access to ART increased from 50,000 to more than 7.5 million between 2002 and 2012 [@pone.0086305-WHO1].

Whilst there is need to scale up provision of this life-saving treatment, there is need to monitor and ensure retention in care of this growing cohort of patients so as to ensure ongoing receipt of ART, evaluate the emergence of medication toxicities, and identify the occurrence of treatment failure in order to switch regimens [@pone.0086305-Geng1]. The high attrition occurring among HIV-infected patients in ART care in SSA has been widely documented, with a meta-analysis of 39 cohorts from SSA showing that patient retention declined from 86% at 6 months to 77% by 36 months after ART initiation. [@pone.0086305-Fox1] In West Africa patient retention has been reported at 76% by 1-year of follow-up whilst in Southern Africa 1-year retention ranges from 67--70% in Mozambique [@pone.0086305-Lambdin1] to 82.7% in Botswana [@pone.0086305-Bussmann1]

To further accelerate ART service coverage in SSA, there have been recommendations to scale-up decentralisation of ART services to primary health-care facilities coupled with task-shifting of service provision to nurses [@pone.0086305-WHO2]. This has resulted in increased ART coverage in Malawi [@pone.0086305-Bemelmans1] and improved adherence and retention [@pone.0086305-Boyer1], [@pone.0086305-Chan1], [@pone.0086305-Fatti1].

Zimbabwe, with a population of 12,9 million is among countries in the sub-Saharan region experiencing a mature HIV epidemic with a decline in prevalence over the last decade from 27.2% in 1998 to 14.0 in 2012 whilst HIV incidence stabilised at 1.0% in 2012 [@pone.0086305-Ministry1]. The adult HIV prevalence observed in the 2010--2011 Zimbabwe Demographic and Health Survey showed slightly higher HIV prevalence in urban areas than in rural areas and ranged by province from 13% in Harare to 21% in Matebeleland South [@pone.0086305-Zimbabwe1]. The number of people living with HIV in 2012 was estimated to be 1.3 million whilst the total estimated number of people in need of antiretroviral therapy (ART) in 2012 was 621,673 adults and 108,263 children (based on a CD4\<350 cells/mm3) [@pone.0086305-Ministry1].

Zimbabwe suffered a socioeconomic crisis between 2001 and 2009 with extreme recession and hyperinflation which significantly affected the national health system. During the crisis, there were extreme shortages of health workers and essential medical supplies [@pone.0086305-Meldrum1]. The National Opportunistic Infections/Antiretroviral Therapy (OI/ART) Programme in Zimbabwe was established in April 2004. Since 2008, both ART initiation and follow-up services have been decentralised to lower level health facilities. In the period under review in this study, there was a remarkable increase in number of health facilities offering ART services and number of patients receiving treatment; by January 2007 there were 101 sites [@pone.0086305-Ministry2] providing treatment to 66,920 patients (11% coverage) [@pone.0086305-Joint1] which rose to 337 sites [@pone.0086305-Ministry3] offering ART to 218,589 patients (49% coverage) [@pone.0086305-Joint2] by December 2009 based on the WHO 2006 Guidelines.

The rapid expansion of ART programmes in settings with weak health systems is associated with high mortality and loss of patients to follow up [@pone.0086305-Mills1], [@pone.0086305-Nachega1]. With the on-going rapid expansion and decentralization of ART in Zimbabwe; it was not clear how treatment outcomes compared across levels of care. The purpose of this study was therefore to i) describe baseline demographic and clinical characteristics, and to determine ii) patient retention in care iii) clinical outcomes and iv) factors associated with attrition among HIV-infected patients enrolled in the National ART Programme in Zimbabwe.

Methods {#s2}
=======

Study Design, Study Population and Sampling {#s2a}
-------------------------------------------

A nationally representative multi-stage retrospective cohort study was implemented using routine data from standard Ministry of Health and Child Care (MOHCC) ART monitoring tools (e.g., facility patient medical records). Between October and December 2010, trained MOHCC personnel abstracted patient-level data from facility medical records onto study questionnaires. Adult patients ≥15 years old at ART initiation who initiated ART between 2007 and 2009 at selected sites, and at least 12 months prior to date of chart abstraction were eligible to be included in the assessment (note: transfer-ins were excluded from the site-level sampling frame).

To achieve a 95% confidence interval (CI) of +/−2.5% around the estimate for a conservative 12-month patient retention of 50%, assuming a design effect of 2 and that 20% of medical records were missing, it was determined that a sample size of ≥3,684 patients was needed. In order to simplify the sampling strategy, we aimed to sample 4,000 charts of HIV-infected adults who initiated ART at least 12 months prior to the date of chart abstraction.

During study planning, MOHCC reported data from May 2008 were used to define the clinic sample frame. By 31 May 2008, 103,806 adults had initiated ART at 104 public sector sites and 70 of the sites had ≥50 adult ART patients and hence they were eligible for inclusion in the sampling frame. Sites were stratified by site size (Small: 50--249 patients; Medium: 250--1000 patients; Large: \>1000 patients) and 40 facilities were selected via stratified probability -proportional-to-size (PPS) sampling. Patient charts were randomly selected at the 40 sites and the number of charts selected was proportional to the size of the site. Patient charts selected for data abstraction were searched for and retrieved by clinic staff. Missing patient charts were replaced by the next eligible patient record on the list of selected charts until the sample size for the site had been reached.

Data from medical records were abstracted onto paper-based questionnaires by trained data abstractors. For quality control purposes, supervisors re-abstracted 10% of all abstracted medical records. Data from the paper questionnaires were then hand entered into an MS Access database and separately scanned into a Teleform database after the data abstraction was completed. Data from the two databases were compared using the COMPARWS Macro [@pone.0086305-Fehd1] in SAS 9.2 (SAS Institute Inc., Cary, NC) to identify discrepancies. Discrepancies were then resolved by referring back to the paper questionnaires before the final dataset was cleaned prior to data analysis.

Ethics review {#s2b}
-------------

This study was approved by the Medical Research Council of Zimbabwe (MRCZ) and by the Institutional Review Board (IRB) of the United States Centers for Disease Control and Prevention. Both institutional review boards waived the need for written informed consent from the participants since data in this study were abstracted from existing medical records.

National ART Guidelines {#s2c}
-----------------------

During 2007--2009, adults were eligible for ART if they were HIV positive and had a diagnosis of World Health Organization (WHO) clinical stage IV, irrespective of CD4+ count; WHO clinical stage III and a CD4+ cell count \<350 cells/µL; or WHO clinical stage I or II and a CD4+ cell count \<200 cells/µL. Co-trimoxazole preventive therapy (CPT) was indicated for all symptomatic HIV-infected patients (clinical stages II, III and IV) and/or if CD4+ cell count was \<200 cells/µL. Psychosocial criteria for ART initiation, included completion of prescribed counselling sessions and an assessment of adherence to CPT in the past 3 months. Adherence to CPT was used to assess the likelihood that the patient would adhere to ART.

According to national ART guidelines CPT adherence is assessed by health workers through pill counts and self-reporting by patients during each clinic visit and then recorded in the health facility held card.

Recommended first-line ART regimens included Stavudine, Lamivudine and Nevirapine. Single drug substitutions within the same drug class were recommended for serious drug toxicities and tuberculosis e.g. Zidovudine was used as an alternate 1^st^ line for Stavudine while Efavirenz was substituted for Nevirapine. After initiating ART, a patient is seen every 2 weeks for the 1^st^ month; thereafter monthly for another 3 months. This is important as patients may present with inter-current illnesses, adverse drug events, or immune reconstitution syndrome. If a patient is stable after the initial 3 months; they are seen every 3 months thereafter. It is government\'s policy to provide ARV medicines free of charge to patients. However, patients are expected to pay consultation fees; laboratory-associated costs such as CD4 tests, Full Blood Count and radiography (CXR) for ruling out chest pathologies.

Recommended clinical and laboratory monitoring indices included patient weight, WHO clinical stage, development of opportunistic infections, complete blood count (CBC), Alanine Transaminase (ALT), serum creatinine, and where possible CD4+ cell counts. Routine clinical monitoring was to be conducted every 3 months; CBC and CD4 were to be conducted every 6 months; and ALT and creatinine were to be conducted every 12 months. CD4 testing was not widely available between 2007 and 2009 as it was mostly available in district hospitals or higher level facilities and at selected primary healthcare facilities which were initiating ART. In 2007 there were 46 CD4 machines and by 2009, 59 facilities in 47 out of the 62 districts countrywide had CD4 machines [@pone.0086305-Ministry4]. CD4 count testing was therefore done at each ART initiating sites if available, as there were no collection and transportation of blood samples to facilities with CD4 count machines. Patient demographic, clinical and laboratory information and visit dates are recorded in MOHCC medical records maintained at the health facility.

Treatment Outcome Measures {#s2d}
--------------------------

During data collection, the most recently documented status of each patient at the last clinic visit date was abstracted and recorded as alive-continued ART, transferred out, stopped, died, lost to follow-up (LFU), defaulted, and other. For this assessment, "retention" referred to a patient who was alive and known to be receiving ART at the same clinic where they initiated ART and "attrition" referred to a patient who was documented as having died, stopped ART, defaulted or was lost to follow-up. A patient defined as "defaulted" had been absent from a healthcare facility for ≤90 days whilst one who was "lost to follow-up" was absent for \>90 days after his/her last scheduled appointment with the health care provider or pharmacy. The date of LFU was recorded as the date of the most recent visit or one day after ART initiation if patients only attended the initiation visit. Patient retention was calculated as the difference between date of ART initiation and the latest clinic visit date. Patients who were documented to have transferred out of a clinic before the time point of interest (either 6, 12, 24 or 36 months of follow-up) were excluded from the numerator and denominator of the relevant retention/attrition proportion.

For time-to-event analyses, patients who transferred to another clinic were censored at the date of transfer. However, for estimating retention proportions at 6, 12, 24, and 48 months, transfers were excluded from the retention analysis. Baseline CD4 was defined as the value on the date closest to ART start date but not more than 182 days prior to that date or more than 1 day after that date. Values for clinical stages, weights and CD4 counts at 6, 12 and 24 months of follow-up, were taken as values obtained on the dates closest to 182, 365 and 730 days, respectively.

Treatment failure was defined using clinical or immunological criteria. Viral load testing was not widely implemented due to the associated prohibitive costs. A patient on ART for at least 6 months presenting with new or recurrent WHO stage 4 condition (clinical failure) or a fall to CD4 count/percentage or persistent CD4 level below 100 cells (immunological failure) were considered treatment failure. The preferred 2^nd^ line ART for adults that failed 1^st^ line ART was Tenofovir, Lamivudine, and Lopinavir/Ritonavir.

Statistical Analysis {#s2e}
--------------------

All analyses were performed using SAS 9.2 (SAS Institute Inc., Cary, NC) and Stata/IC 10.1 (StataCorp, 2009, Stata Statistical Software: Release 10.1, College Station, TX). Statistical analyses were weighted to account for unequal probabilities of selection and accounted for the complex design of the survey (i.e. stratification and clustering).

Missing data were assumed *missing at random* (MAR) [@pone.0086305-Rubin1] and were multiple imputed via chained equations using the ice [@pone.0086305-Royston1]--[@pone.0086305-Royston3] procedure in Stata. Twenty imputed datasets were created and estimates were combined according to Rubin\'s rules [@pone.0086305-Rubin1] using the mim procedure [@pone.0086305-Royston4]. The imputation model included the Nelson-Aelen estimate of cumulative hazard [@pone.0086305-White1], baseline demographic and clinical variables, and the event indicator. Time-to-event data were complete for all individuals. Twenty-five patients were lost to follow-up after their first clinic visit and were assigned one day of person-time.

Stratified Kaplan-Meier curves were used to graphically assess retention proportions. These analyses were limited to the first imputed dataset. Cox proportional hazards models were used to identify factors (e.g., year of ART initiation, gender, baseline CD4 count, baseline WHO stage, baseline body weight, active TB treatment, baseline haemoglobin) associated with attrition based on prior research. Hazard ratios (HRs), adjusted hazard ratios (AHRs) and their respective 95% confidence intervals (CI) and p-values were calculated. In multivariate-analysis HRs were adjusted for the potential confounding effects of sex, marital status, rural/urban location of health facility, baseline CD4 count, baseline WHO staging, baseline weight, prescribed CTX, level of health care and site size of ART clinic. The proportional hazards assumption was assessed via a variety of methods including log-log plots and Kaplan-Meier versus Cox predicted plots and results of these analyses suggested that the proportional hazards assumption appeared to be reasonable.

Results {#s3}
=======

Demographic and clinical characteristics of ART patients and characteristics of ART sites including clinical practices {#s3a}
----------------------------------------------------------------------------------------------------------------------

A total of 3,919 medical charts of eligible ART patients were located and abstracted. Data were missing at baseline for 630 (16%) patients for WHO clinical stage, 2,085 (53%) for CD4 T-cell count, 1,049 (26.8%) for body weight, 3,021 (77%) patients for haemoglobin and 825 (21%) for cotrimoxazole prescription. [**Table 1**](#pone-0086305-t001){ref-type="table"} describes analysis results for both the original and imputed datasets; in the following text, weighted imputed data are reported.

10.1371/journal.pone.0086305.t001

###### Demographic and clinical characteristics of patients at ART initiation and characteristics of ART sites, including clinical practices.

![](pone.0086305.t001){#pone-0086305-t001-1}

                                                        All           Multiple Imputation (N = 3,919)
  ----------------------------- ------- ------- -------------------- ---------------------------------
  Sex                                                                
  Female                         2,514   3,907   64.1% (62.2--65.9)         64.0% (62.2--65.9)
  Male                           1,393   3,907   35.9% (34.1--37.8)         36.0% (34.1--37.8)
  Missing                         12     3,919          0.3%                        --
  Age At ART Start (Years)                                           
  All                            3,733   3,733      37 (32--45)                 37 (32--45)
  Missing                         186    3,919          0.0%                        --
  Female                         2,388   2,388      36 (31--44)                 36 (31--44)
  Male                           1,335   1,335      39 (34--48)                 39 (34--48)
  Marital Status                                                     
  Single/Divorced                 651    3,003   21.8% (18.1--25.4)         22.0% (19.0--25.2)
  Married/Cohabiting             1,577   3,003   52.5% (49.8--55.2)         52.4% (50.1--54.7)
  Widowed                         775    3,003   25.7% (22.1--29.4)         25.5% (22.5--28.5)
  Missing                         916    3,919         23.4%                        --
  WHO Stage                                                          
  I/Ii                            390    3,289   12.4% (6.8--18.1)           14.4% (8.6--20.1)
  Iii                            2,413   3,289   73.5% (66.9--80.1)         70.5% (63.9--77.1)
  Iv                              486    3,289   14.1% (9.7--18.4)          15.1% (11.4--19.0)
  Missing                         630    3,919         16.1%                        --
  CD4 T-Cell Count (Cells/Ml)                                        
  ≥200                            712    1,834   22.7% (19.5--25.9)         24.1% (19.6--28.6)
  50--\<200                      2,206   1,834   54.9% (51.2--58.7)         53.4% (49.8--57.1)
  \<50                           1,875   1,834   22.4% (20.2--24.6)         22.4% (19.8--25.1)
  Missing                        2,085   3,919         53.2%                        --
  Weight                                                             
  \>60 Kg                         779    2,870   26.5% (22.9--30.1)         26.8% (23.5--30.0)
  45--60 Kg                      1,722   2,870   60.4% (57.9--62.3)         60.0% (57.6--62.3)
  \<45 Kg                         369    2,870   13.1% (10.3--16.0)         13.3% (10.8--15.8)
  Missing                        1,049   3,919         26.8%                        --
  Prescribed CTX                                                     
  Yes                            2,985   3,094   96.7% (95.0--98.3)         96.6% (95.2--98.1)
  No                              109    3,094    3.3% (1.7--5.0)             3.4% (1.9--4.8)
  Missing                         825    3,919         21.1%         
  Site Type                                                          
  Rural                          1,975   3,919   46.7% (22.0--71.3)         46.7% (22.0--71.4)
  Urban                          1,944   3,919   53.3% (28.7--78.0)         53.3% (28.6--78.0)
  Missing                          0     3,919          0.0%                        --

At enrolment into OI/ART, patient median age was 37 years, and 64% were female of whom 5.8% were pregnant. Fifty-two percent of the patients were married or cohabitating and 25.5% were widowed. Fifty-three percent of patients initiated treatment at an urban clinic and 46.7% initiated treatment at a rural clinic. Almost three quarters (72.6%) of patients initiated ART at a district or mission hospital; 16.8% initiated ART at a central or provincial hospital; and 10.6% initiated treatment at a primary healthcare facility.

Median CD4+ cell count at baseline was 121 cells/µL. Median CD4 cell count at baseline was slightly lower in males (104 cells/µL) than in females (127 cells/µL). At baseline, 22.4% of patients had a CD4 cell count less than 50 cells/µL, and 53.4% had a cell count between 50 and 200. A higher proportion of males had a CD4+ cell count below 50 cells/µL than females.

In terms of WHO clinical staging, 70.5% were diagnosed with stage III disease, 15.1% were diagnosed with stage IV disease, and the remaining were diagnosed with stages II and I disease. A slightly higher proportion of males were diagnosed with stage IV disease compared to females (males -- 16.4% and females- 12.8%).

At baseline, 13.3% of patients weighed less than 45 kilograms (kgs) and 60% weighed between 45 and 60 kgs. The median weight of females was 53.2 kgs and of males was 57 kgs.

Treatment for tuberculosis at the time of enrolment into an OI clinic was documented for 12% of the 2,231 patients with information about TB treatment at OI clinic enrolment. A higher proportion of male ART patients were on TB treatment at OI clinic enrolment than female ART patients.

The majority of ART patients (96.6%) were prescribed CTX at baseline and 100% of the 3,759 patients with documented data were prescribed a first-line regimen. Three percent of patients had documented drug substitutions for active TB, toxicity, pregnancy and other reasons. Only six (0.2%) of patients had documented treatment failure and were switched to second-line antiretroviral treatment. Fifteen patients were documented to have stopped ART because of drug toxicity, pregnancy and other reasons.

Patient outcomes {#s3b}
----------------

Of 3,919 patients who initiated ART, 90.7%, 78.1%, 68.8% and 64.4% remained alive on ART at their initiating site after 6, 12, 24 and 36 months, respectively ([**Table 2**](#pone-0086305-t002){ref-type="table"}). Retention on ART appeared higher in females when compared to males at 24 months (71.1% vs 64.6%) and at 36 months (66.9% vs. 59.7%).

10.1371/journal.pone.0086305.t002

###### Retention of patients after 6, 12, 24, and 36 months.

![](pone.0086305.t002){#pone-0086305-t002-2}

                             Total                      Females                      Males
  ----------- ------- ------------------- ------- ------------------- ------- -------------------
  6 months     3,739   90.7 (86.1--93.8)   2,413   91.9 (87.3--94.9)   1,316   88.5 (83.4--92.2)
  12 months    3,641   78.1 (69.7--84.7)   2,352   79.6 (71.1--86.2)   1,280   75.3 (66.6--82.3)
  24 months    2,003   68.8 (58.5--77.5)   1,286   71.1 (60.3--80.0)    711    64.6 (54.1--73.8)
  36 months     806    64.4 (55.7--72.3)    522    66.9 (56.6--75.8)    282    59.7 (51.1--67.8)

Note: These analyses are not based on imputed data.

Median follow-up duration was 1.36 years. By 6 months, 4.1% had died and 4.9% had been LFU; by 12 months, 4.8% had died and 16.1% had been LFU; by 24 months, 6.7% had died and 23.5% had been LFU; and by 36 months 8.5% had died and 25.2% were LFU. Of patients who died, 59.8% died within 90 days of starting ART. Of patients who were LFU, 15.6% were lost within 90 days and 68% were lost within 365 days of starting ART.

**Clinical improvement** was seen among both male and female patients. Increases in body weight and in CD4 cell counts were observed between baseline and follow-up appointments at 6, 12, and 24 months among patients with weight and/or CD4 cell count data. [**Table 3**](#pone-0086305-t003){ref-type="table"} describes weight gains in ART patients.

10.1371/journal.pone.0086305.t003

###### Median weight gains (kilograms) during ART stratified by gender.

![](pone.0086305.t003){#pone-0086305-t003-3}

             6-month gains    12-month gains   24-month gains    36-month gains                                            
  -------- ----------------- ---------------- ----------------- ---------------- ----------------- ----- ----------------- -----
  All       3.0 (−0.8--7.0)       1,621        4.5 (0.0--9.0)        1,444        5.0 (1.0--10.0)   665   6.0 (0.0--11.0)   209
  Female    3.0 (−1.0--7.0)       1,058        5.0 (0.0--10.0)        955         5.0 (1.0--12.0)   429   6.0 (0.0--11.0)   134
  Male      3.0 (0.0--6.8)         560         4.0 (0.0--8.0)         486         5.0 (1.0--9.8)    234   4.0 (0.5--9.0)    73

Note: These analyses are not based on imputed data.

Increases in CD4+ cells were also observed after ART initiation among the few patients with CD4+ count measurements ([**Table 4**](#pone-0086305-t004){ref-type="table"}). For female patients, median CD4+ count gains from baseline were 122, 171, and 265 cells/µL at 6, 12, and 24 months, respectively. For male patients, median CD4+ count gains from baseline were 125, 130, and 179 cells/µL at 6, 12, and 24 months, respectively.

10.1371/journal.pone.0086305.t004

###### Median CD4 T-cell count (cells/µL) gains during ART stratified by gender.

![](pone.0086305.t004){#pone-0086305-t004-4}

            6-month gains   12-month gains   24-month gains                         
  -------- --------------- ---------------- ---------------- ----- ---------------- -----
  All       122 (65--189)        222         157 (85--240)    279   252 (162--353)   162
  Female    122 (68--193)        139         171 (89--252)    183   265 (180--367)   106
  Male      125 (63--172)         83         130 (80--211)    96    179 (113--298)   56

Note: These analyses are not based on imputed data.

Factors associated with attrition {#s3c}
---------------------------------

[**Table 5**](#pone-0086305-t005){ref-type="table"} shows the results of univariate and multivariable analyses of factors associated with attrition.

10.1371/journal.pone.0086305.t005

###### Factors associated with attrition including patient characteristics at ART initiation, clinical practices and healthcare facility type and location.
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                                 Attrition                                                                             
  ----------------------------- ----------- ------ ------ ----------------------- ----------- ------------------------ -----------
  Sex                                                                                                                  
  Female                           2,514     19.3   19.3            1.0                                 1.0                --
  Male                             1,393     24.0   24.0   **1.22 (1.07--1.39)**   **0.003**   **1.24 (1.08--1.43)**    **0.004**
  CD4 T-cell count (cell/µL)                                                                                           
  \>200                             402      14.8   19.4            1.0               --                1.0                --
  \>50--≤200                       1,031     13.2   19.5     1.03 (0.76--1.39)       0.861       0.97 (0.74--1.26)        0.806
  \<50                              401      22.7   25.8   **1.36 (1.01--1.85)**   **0.045**     1.22 (0.89--1.67)        0.189
  WHO Stage                                                                                                            
  Stage I/II                        390      15.8   17.5            1.0               --                1.0                --
  Stage III                        2,413     19.1   19.9     1.16 (0.76--1.77)       0.481       1.15 (0.74--1.78)        0.531
  Stage IV                          486      26.6   30.3   **1.73 (1.19--2.50)**   **0.006**   **1.73 (1.14--2.61)**    **0.012**
  Weight                                                                                                               
  \>60 kgs                          779      15.2   16.3            1.0               --                1.0                --
  45--60 kgs                       1,722     19.0   20.4   **1.25 (1.03--1.51)**   **0.024**   **1.25 (1.04--1.51)**    **0.020**
  \<45 kgs                          369      33.4   34.7   **2.07 (1.53--2.79)**   **0.000**   **2.03 (1.43--2.87)**    **0.000**
  Prescribed CTX                                                                                                       
  Yes                              2,985     16.7   20.3            1.0               --                1.0                --
  No                                109      34.5   39.5   **1.82 (1.22--2.72)**   **0.005**   **1.94 (1.21--3.09)**    **0.007**
  Level of Healthcare                                                                                                  
  Primary healthcare facility       415      8.4    8.4             1.0               --                1.0                --
  District/Mission hospital        2,844     20.1   20.1     2.24 (0.81--6.20)       0.116     **3.49 (1.09--11.20)**   **0.036**
  Central/Provincial hospital       660      29.8   29.8     3.16 (1.15--8.72)     **0.027**   **3.21 (0.96--10.75)**   **0.058**
  Site Type                                                                                                            
  Rural                            1,975     14.8   14.8            1.0               --                1.0                --
  Urban                            1,944     27.8   27.8   **1.75 (0.99--3.09)**   **0.054**   **2.13 (0.95--4.77)**    **0.064**

Male sex was associated with an increased risk of attrition (*AHR* 1.24; *p* = 0.004). Baseline WHO stage IV was associated with an increased risk of attrition (*AHR* 1.73; p = 0.012) as compared with WHO stages I/II. A baseline CD4 cell count\<50 (*HR* 1.36, *p* = 0.05) was associated with higher attrition as compared with CD4 cell count \>200 in univariate analysis, however, no associations between CD4 cell count and attrition were observed in the final multivariable survival model. Patients with baseline weights of 45--60 kilograms (*AHR* 1.25; *p* = 0.02) and \<45 kilograms (*AHR* 2.03; *p* = .000) at baseline had an increased risk of attrition as compared with those patients with weights \>60 kilograms ([Figure 1](#pone-0086305-g001){ref-type="fig"}).

![Retention stratified by weight at baseline.](pone.0086305.g001){#pone-0086305-g001}

While the majority of patients were prescribed cotrimoxazole prophylaxis at baseline, those who did not receive a cotrimoxazole prescription had significantly increased risk of attrition (*AHR* 1.94; *p* = .007).

Initiating ART at an urban site, as compared with a rural site, was marginally associated with attrition (*AHR* 2.13; *p* = 0.06). Initiating ART at a central/provincial hospital (*AHR* 3.21; *p* = 0.06) or at a district/mission hospital (*AHR* 3.49; *p* = 0.04) as compared with a primary healthcare clinic, was marginally associated with a higher risk of attrition ([Figure 2](#pone-0086305-g002){ref-type="fig"}).

![Retention stratified by level of healthcare.](pone.0086305.g002){#pone-0086305-g002}

Discussion {#s4}
==========

Clinical outcomes and retention in care were similar to findings in other Sub-Saharan African countries despite severe challenges to the health system, hence demonstrating that rapid ART scale-up with good clinical outcomes is feasible even under difficult circumstances. Retention rates in Zimbabwe are very similar to those estimated by Fox and Rosen [@pone.0086305-Fox1] in a recent meta-analysis of published cohort data from 16 countries in sub-Saharan Africa in which estimated retention rates of ART patients at 6, 12, 24 and 36 months, were 86.1%, 80.2%, 70.0% and 64.6% respectively. Whilst our findings may have been similar to those in other Sub-Saharan African countries, we hypothesized that they would be worse. This is in view of existing hyperinflation in Zimbabwe during the period under review whereby cumulative inflation between 1997 and 2007 was 3.8 billion percent whilst the official inflation figure for February 2008 was 165,000 percent [@pone.0086305-Hanke1]. This hyperinflation was associated with increasing emigration of doctors and shortages of essential medical supplies in health facilities [@pone.0086305-Meldrum1]. Despite this situation we managed to have comparatively similar findings through funding from bilateral aid and international multilateral institutions such as Global Fund to fight AIDS,

Tuberculosis and Malaria (GFTATM) and the Expanded Support Programme for HIV and AIDS (ESP) which ensured antiretroviral medicines were procured and distributed countrywide among other interventions. There was also support from ESP towards the human resource retention scheme [@pone.0086305-Ministry5] which supported primary counsellors who offered treatment adherence counselling and psychosocial support to patient whilst a significant amount was channelled towards retention of critical staff such as doctors who were responsible for initiating patients on ART, managing co-morbidities and complications as well as mentoring nurses in providing follow-up care. In 2009 alone, international sources contributed over 75% of total HIV spending [@pone.0086305-Joint2] since internal funding sources such as the National AIDS levy were insignificant due to the eroded value of the Zimbabwe dollar.

The median CD4 cell count at ART initiation was low although this was slightly higher than that reported in a systematic review of 39 patient cohorts in Sub-Saharan Africa [@pone.0086305-Fox1]. We also note that nearly half of the cohort initiated ART at very low CD4 counts (50--200 cells). Whilst ART was recommended in all patients eligible for ART according to 2006 WHO guidelines [@pone.0086305-Gilks1] such patients with very low CD4 counts were prioritized and fast tracked for ART over those with higher CD4 counts as these usually have higher risk of dying. Slightly over half of the cohort did not have documentation of a baseline CD4 count test. Further analysis shows that these patients without CD4 counts did not constitute any specific sub-group of patients. Scale up of point-of-care CD4 count machines could greatly improve linkage to ART care and patient retention as they have been shown locally to be more suitable for immediate decision making, improve testing access in both rural and urban settings and can also be used by nurses when compared to conventional laboratory CD4 machines [@pone.0086305-MtapuriZinyowera1].

For those ART patients in Zimbabwe with documented follow-up data, there were some signs of immunologic and clinical improvement. Median gains in CD4+ cell counts at 6, 12, 24 and 36 months were similar to those reported from Rwanda [@pone.0086305-Lowrance1], Mozambique [@pone.0086305-Auld1] and Cote d\'Ivoire [@pone.0086305-Toure1] and other low- and high-income settings [@pone.0086305-Braitstein1]. These immunologic gains in the absence of virological monitoring maybe highly associated with viral load suppression although it has recently been shown that immunologic monitoring coupled with monitoring viral load and duration on ART is very useful in assessing risk of patient mortality [@pone.0086305-Brennan1]. In our study the treatment failure rate which was based on a clinical/immunologic definition was lower than the average treatment failure rate of 2.64% reported for Africa in a systematic review by Renaud-Thiery F et al [@pone.0086305-RenaudThery1] when similarly based on the clinical/immunologic criteria. However, the clinical/immunologic criteria for treatment failure is known to be less sensitive in comparison to virological monitoring [@pone.0086305-Moore1] and treatment failure rates were found to be approximately three times higher when viral load was used to define failure in the systematic review by Renaud-Thiery et al [@pone.0086305-RenaudThery1]. In Zimbabwe, findings from routine cohort monitoring at 12 sentinel sites for HIV drug resistance conducted between 2009 and 2011 show that 10.4% of 958 HIV-infected patients had viral load \>1000 copies/ml at 12 months after starting ART, and upon excluding those with baseline gene mutations the proportion that had acquired HIV drug resistance was 8.9% [@pone.0086305-Ministry6]. This highlights a need for integration of viral load monitoring into routine ART care.

Median gains in weight were also noted in this study and such observations during antiretroviral therapy have been associated with better patient outcomes [@pone.0086305-Madec1]. Similar to our setting, the same has been reported in Rwanda [@pone.0086305-Lowrance1] and Mozambique [@pone.0086305-Auld1]. Routine recording of weight was notably a poor practice both at ART initiation and in follow up visits in this study and needs to be scaled up since WHO recommends monitoring weight [@pone.0086305-World1] as a useful indicator of a patient\'s response to ART.

As found in other sub-Saharan African countries, retention of patients initiating ART at primary healthcare facilities in Zimbabwe was better than for those initiating ART at higher levels of care, in particular district/mission hospitals [@pone.0086305-Chan1], [@pone.0086305-Fatti1], [@pone.0086305-Bedelu1], [@pone.0086305-Decroo1]. In further analysis we noted that there were more LFTUs in district/mission hospitals compared to primary care facilities. Whilst these LFTUs could have been silent deaths they could as well be patients who unofficially transferred from centralised services to PHCs where they can access better quality medical attention as found in a systematic review of mostly Sub-Saharan African studies [@pone.0086305-Brinkhof1]. During the study period under review, ART initiations were mostly led by doctors who were mostly situated in higher level health facilities due to their shortage. It is therefore likely that patients would travel from rural settings to district or mission hospitals, for ART initiations and there after unofficially transfer to other less congested peripheral facilities for follow-up care. This in part may overestimate attrition levels in these higher level facilities. To limit such potential biases, transfers-in were not sampled during data collection whilst official transfers-out where eliminated from the analysis.

This further suggests the importance of continuing the decentralization of OI/ART services through the accreditation of peripheral health facilities and outreach sites so that they can conduct ART initiations as described in the 2011 Zimbabwe Guidelines for the Decentralization of OI/ART Services [@pone.0086305-Ministry7]. This should also be coupled with endorsing nurse-led ART initiation, given the high shortage of medical doctors. In our view decentralisation improved patient retention in the National ART Programme, particularly at primary care facilities by decongesting ART initiations at higher level facilities although this may inevitably have contributed to high losses-to-care of patients from centralised facilities with high patient volumes who unofficially transferred to primary health facilities were they could access better quality of medical care and follow-up. To address future attrition we propose adoption of patient adherence groups for stable ART patients. In an urban setting in South Africa, these adherence groups have resulted in a 57% reduction in loss-to-care compared to those attending routine nurse-led care [@pone.0086305-LuqueFernandez1] whilst in rural Mozambique they have resulted in a remarkable 1-year patient retention of 97% [@pone.0086305-Decroo1].

As reported by other ART Programmes in sub-Saharan Africa, male sex and advanced disease at ART initiation were associated with patient death or loss to follow-up [@pone.0086305-Lowrance1]--[@pone.0086305-Toure1], [@pone.0086305-Stringer1]--[@pone.0086305-Ekouevi1]. In our study, proportionally more women (64%) than men (36%) were on ART as reported by other Southern African countries [@pone.0086305-Muula1]. This corresponds with national HIV testing patterns in Zimbabwe in which fewer women (42%) than men (62%) report never having been tested for HIV [@pone.0086305-Zimbabwe1] and also with the observation that male HIV patients in sub-Saharan Africa are more likely than females to have advanced HIV disease at ART initiation and to be at increased risk of LTFU and/or death [@pone.0086305-May1], [@pone.0086305-Mills2], [@pone.0086305-Hawkins1].

In many African settings, women have better access than men to HIV testing and treatment services through integration of routine "opt-out" provider-initiated testing and counselling in antenatal care settings [@pone.0086305-Staveteig1] as an entry point into prevention-of-mother-to-child HIV transmission (PMTCT) services, even though attrition rates between testing HIV-positive in pregnancy and accessing ART continue to be unacceptably high [@pone.0086305-Ferguson1], [@pone.0086305-Muchedzi1]. A recent study by Takarinda and colleagues [@pone.0086305-Takarinda1] suggests that even when men do have access to HIV testing and counselling they decline it. HIV testing rates can be scaled up through innovative strategies such as roll-out of routine opt-out mobile, home-based or work-place voluntary testing and counselling [@pone.0086305-Matovu1]--[@pone.0086305-Kuwane1] which may improve male participation in order to achieve earlier HIV diagnosis and also provider initiated testing and counselling in a healthcare setting can improve testing for both genders. Strategies aimed at improving linkage to care from HIV testing may also help achieve earlier treatment and resultantly improve patient treatment outcomes.

A large percentage of the cohort had low body weight at baseline and consistent with other ART Programmes [@pone.0086305-Lowrance1], [@pone.0086305-Auld1], [@pone.0086305-May1] the probability of retention was lower in patients with low body weight at ART initiation. Although it is not known whether undernourishment is causally related to poor ART outcomes or is merely associated [@pone.0086305-Koethe1], hunger is a frequently reported barrier to adherence and the side effects and toxicity of some ARVs can be potentiated if taken without food [@pone.0086305-Koethe2]. Adoption of food supplementation as a strategy aimed at increasing patient retention would be useful in our setting. This strategy has been shown to improve adherence to ART among food-insecure adults in Zambia [@pone.0086305-Cantrell1] and also is associated with reduced morbidity and hospitalisations [@pone.0086305-Weiser1].

Anaemia has been shown to be an independent indicator of mortality and of disease progression among HIV-infected persons in sub-Saharan Africa [@pone.0086305-Stringer1], [@pone.0086305-May1], [@pone.0086305-OBrien1], [@pone.0086305-Ojikutu1]. Unfortunately, levels of anaemia could not be determined in our study because only 20.2% of patients had a documented haemoglobin level at baseline and even fewer had documented haemoglobin levels at follow-up visits. Zimbabwe has begun gearing up routine clinical laboratory testing for HIV-infected patients which should improve the capacity of clinicians to screen for anaemia.

Attrition was closely associated with advanced disease status at ART initiation as reported by ART programmes throughout sub-Saharan Africa [@pone.0086305-Brinkhof1], [@pone.0086305-Lawn1]. Clinical predictors of attrition in Zimbabwe at initiation of ART included WHO clinical stage III and low body weight (\<45 kg). Whilst those in WHO stage IV were at increased risk of attrition compared to those in WHO stage I/II, they constituted a small proportion of the cohort. The majority where in WHO stage III at ART initiation and although they were not significantly at higher risk of attrition, these patients had advanced HIV disease and where therefore also at increased risk of having poor outcomes compared to those in stage I/II. Data from South Africa and other countries demonstrate that starting ART earlier (at CD4\<350 cells/µL) results in improved treatment outcomes [@pone.0086305-Fox2]. Similar to other programmes [@pone.0086305-Auld1], [@pone.0086305-Brinkhof1], [@pone.0086305-Stringer1], [@pone.0086305-May1], a large proportion of reported mortality in our study population occurred within 6 months of initiating ART. During the period of our study, adults infected with HIV were eligible for ART if they presented with WHO clinical stage IV and/or CD4+ \<200 cells/µL. It is well known from literature that initiation of ART with poor health at baseline (specifically CD4 counts\<200cells/ml or WHO stage IV or V) can lead to immune reconstitution inflammatory syndrome which can occur within days to months from ART initiation and has clinical effects ranging from a mild, self-limiting illness to severe morbidity and mortality. [@pone.0086305-Hirsh1], [@pone.0086305-Elston1] Our findings underscore the importance of initiating treatment at an earlier disease stage as recommended by the recently published 2013 WHO Consolidated HIV Guidelines [@pone.0086305-World2].

The 2013 Consolidated HIV Guidelines present opportunities for Zimbabwe to provide early HIV treatment and care services for HIV infected people using a higher CD4 threshold of \<500. In 2013 alone, the number of people in need of treatment will increase by 25% from 685,360 (based on the 2010 guidelines) to 857,842 [@pone.0086305-Ministry1]. It is likely that the country will adopt Tenofovir +Lamivudine+Efavirenz, as the preferred 1^st^ line ART regimen for adults and adolescents. Although more costly than stavudine-based regimens; it is hoped that as more countries adopt the guidelines and order large volumes of medicines, the drug price for tenofovir-based regimens will decline over time with economies of scale. It is feasible though that Zimbabwe will successfully adopt and implement the 2013 WHO HIV guidelines using the recently approved Global Fund HIV grant of USD 555 million.

Despite our study having a large sample which enables us to confidently infer our findings to the entire national ART programme, there were limitations to our study. These limitations were mainly related to data abstraction of routinely collected programme data hence this accounted for missing data in a number of variables collected. We were also unable to establish true patient outcomes for those patients that were classified as LFTU or defaulters. Also the exclusion of patients that transferred out or transferred into the selected ART sites may limit inference of our findings to this patient group although further comparison of the abstracted "transfer-out" patient group to the rest of the cohort showed no differences in baseline characteristics. The above mentioned limitations may therefore lead to biased estimates on patient retention and attrition-associated factors in the national patient cohort.

Conclusion {#s5}
==========

The assessment covered a difficult period for Zimbabwe and despite this, the rapid scale-up of ART has been remarkable. Also whilst retention and clinical outcomes are comparable or better than those reported from programmes in other sub-Saharan African countries, there is still need to monitor and improve on retention, and some strategies may include the adoption of ART adherence clubs [@pone.0086305-Bedelu1] and issuing out of mobile phone short message services as drug pick-up and clinic visit reminders to patients [@pone.0086305-Lester1] as shown in other settings. Adoption of food supplementation can be another feasible strategy to improve patient retention among food insecure adults.

In addition, our findings indicate that increased efforts are needed to ensure that persons with HIV seek care and initiate treatment before they have advanced disease and to expand access of services through decentralisation and targeted services (e.g., for men).

HIV testing rates and linkages to care, especially for men, need to be improved (perhaps through the provision of services in non-traditional venues) in order to achieve earlier diagnosis and treatment whilst CD4 cell count testing needs to be scaled up at district level to assess ART eligibility [@pone.0086305-Ferguson1], [@pone.0086305-Ojikutu1] and this can be through the use of CD4 point-of-care machines.
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